AstraZeneca, Ionis slip as ATTR-CM drug fails Phase 3
Phase 3negativeWainuaNegative
AI Analysis
Summary
AstraZeneca and Ionis's late-stage ATTR-CM drug Wainua failed its Phase 3 trial, surprising analysts given the previously proven efficacy of its transthyretin silencing mechanism. The failure caused both companies' stock prices to decline.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Not Met
Outcome Details
Phase 3 trial failed; mechanism of silencing transthyretin protein expression previously proven effective
Importance:8/10
Sentiment:
-0.90
Phase 3 failureATTR-CMtransthyretinstock declineclinical setback
Read the original article
Published by BioSpace on July 9, 2026 12:53 PM